from one block; by assembling the resulting series of scanning SAXS data, a full 3D image was reconstructed. The obvious disadvantage of that technique compared with the currently reported ones is that the bone sample was destroyed.
T he pathogenic bacterium Staphylococcus aureus causes thousands of deaths each year. Therapy is sometimes unsuccessful, partly because antibiotic-resistance genes are spreading worldwide. However, even strains of S. aureus that lack resistance genes are often difficult to kill with available anti biotics; it has been suggested that the bacteria 'hide' inside host cells. This hypothesis inspired Lehar et al. 1 , who, on page 323 of this issue, present a construct in which an antibiotic is linked to an antibody that binds to the pathogen's surface. Alone, this 'prodrug' is inactive, but when prodrug-coated bacteria enter host cells, enzymatic activity releases the anti biotic. In mouse models of S. aureus infection, this strategy was strikingly more potent than standard antibiotic treatment.
Antibiotics are a pillar of modern medicine, but they are not effective in all cases. There are at least three explanations for this. First, important pathogenic bacteria, including many S. aureus strains, have acquired resistance against standard antibiotics 2 . Second, the pathogen may hide in host sites that cannot be reached by antibiotic molecules, or where the environmental conditions, such as high acidity, render the antibiotics inactive. And third, in certain circumstances, bacteria can switch to a 'persistent' lifestyle that makes them insensitive to antibiotics 3 . The switch to persistence is still not completely understood but can occur in some pathogens when they enter host cells.
In S. aureus, a range of virulence factors manipulate host-cell processes, prohibit efficient immune responses and fuel infections in wounds, the bloodstream and other sites. In the absence of antibiotic-resistance genes, several different classes of antibiotic are used to treat S. aureus infections; rifampicin anti biotics are sometimes employed to target intracellular reservoirs of the bacterium. However, these classic antibiotics are often unable to cure the infection.
Lehar and colleagues speculated that this failure is due to either insufficient accessibility of the antibiotic or insufficient activity against intracellular S. aureus. In an attempt to overcome these problems, the researchers first generated a rifampicin derivative (a 'rifalogue') with altered physicochemical properties that gives superior activity against S. aureus cells that have switched to a persistent lifestyle. Next, they identified an antibody that tightly binds to sugar structures found on the surface of all S. aureus strains tested. Then they covalently joined these two components by using a chemical bridge that can be broken by protease enzymes that are present at the intra cellular sites where S. aureus is thought to hide out (Fig. 1) . Strikingly, in a mouse infection model, this antibody-antibiotic conjugate (AAC) was much more effective at reducing pathogen loads than two conventional antibiotics currently used to treat recalcitrant S. aureus infections.
This approach is reminiscent of antibodytargeted prodrug strategies that are currently used in cancer therapy 4 , and these proof-ofprinciple data suggest that targeted antibiotic delivery is a promising strategy for fighting obstinate intracellular pathogens. It remains to be seen whether AACs are as efficient at 1 report the use of a new technique to detect an emission signal from a growing planet. This discovery has farreaching implications for our understanding of the planet-formation process and of the properties of young planets.
When a star is born, a flat rotating disk of gas and dust forms around it, known as the circumstellar disk. This disk continuously transports dust and gas inward to feed the young star for millions of years, a process known as disk accretion. Planets are thought to form from the leftover material from this disk. Earth, for example, was born in the circum stellar disk surrounding the young Sun 4.6 billion years ago. But little is known about how microscopic dust particles can grow 14 orders of magnitude bigger to become a giant planet within the relatively short lifetime of the disk. Finding young planets in circumstellar disks should provide important clues about when, where and how young planets are born.
But finding planets is difficult because they are small and dim. The presence of most known planets has therefore been inferred from observations of the stars around which they revolve. For instance, the Kepler satellite 2 has discovered more than 1,000 planets by measuring the tiny dimming of stellar light that occurs when a planet passes in front of its star.
Such methods cannot be used to find young planets around young stars, because such stars are highly active and the light they emit is variable. Most attempts to find young planets use 10-metre-diameter optical telescopes to directly image planets in circumstellar disks. Disks with large cavities are particularly targeted 3 , because such cavities are thought to be opened up by giant planets in orbit around the central star.
In 2012, a protoplanet candidate 1,000 times fainter than its host star was discovered 4 in a system called LkCa 15 (Fig. 1) . The central star of this system is similar to our Sun, but is only 2 million years old. The Sun-like star has a circumstellar disk with a cavity 50 astronomical units in radius (1 au is the distance from Earth to the Sun).
The protoplanet candidate, called LkCa 15 b, resides inside the cavity, 16 au away from the central star. But the nature of LkCa 15 b is unclear -it is redder than would be expected for a young planet. Several young planet candidates 5, 6 have since been discovered in other circumstellar disks, and they are all quite red. This has led to the hypothesis that the detected red objects are young planets with circumplanetary disks. When a planet is born, a rotating circumplanetary disk of gas and dust forms around it, similar to the circumstellar disks around young stars. As the accreting disk feeds the nascent planet, it releases energy and becomes bright. The emission from such a disk should be redder than the planet itself 7 . In their study, Sallum et al. searched for a signature of young planets: Hα photons, which are emitted from hydrogen atoms only when a circumplanetary disk accretes onto a planet. If a young planet has strong magnetic fields, the fields form a large magnetosphere around the planet, which can truncate the circumplanetary disk 7, 8 . The material in the disk therefore has to follow the planet's magnetic fields to accrete onto the planet. During this accretion process, the magnetosphere can be as hot as 10,000 kelvin, which is what causes hydrogen atoms to emit Hα photons 9 . Although the emission of Hα photons has been widely observed when circumstellar disks accrete onto young stars, Sallum and colleagues are the first to directly image accreting
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Growing planet brought to light
Thousands of extrasolar planets have been discovered, but none is a planet in its infancy. Observations have finally been made of a young planet growing in its birthplace -opening the way to many more such discoveries. See Letter p.342 treating bacterial infections in humans as they are in mice, especially in chronically infected patients, who often already have antibodies against S. aureus. Such antibodies may shield the bacterial surface from AAC binding, and therefore interfere with the targeting of the prodrug. Moreover, because the antibiotic makes up only around 1% (by mass) of the current construct, the AAC would have to be applied at the equivalent of more than a gram per dose for an adult human patient. This might be improved in the future by replacing the antibody with smaller surface-targeting entities.
Why is the AAC approach so much more effective than standard antibiotics? One reason is that the rifalogue is more efficient than rifampicin at killing persistent S. aureus cells. Another is that the kinetics of drug distribution, excretion and inactivation seem to be favourably affected by its fusion to the antibody. Coating bacterial cells with the antibody-bound prodrug may also steer the bacteria to be taken up into intracellular compartments (lysosomes) that have high levels of the enzymes needed to release the antibiotic 5 . And accumulation of the AAC on the pathogen's surface may cause particularly high local concentrations of the bacteria in the intracellular hideout. It remains to be seen which of these mechanisms account for the in vivo potency of the AAC.
Compared with conventional antibiotic therapy, the prodrug approach is likely to reduce both the emergence of antibiotic resistance (by reducing the exposure of other bacteria to the active drug) and the disruption of the body's normal communities of microorganisms. There is still plenty of scope for optimizing the targeting moieties and the chemical bridges 6 . Moreover, the strategy may allow researchers to revisit older antimicro bials that were not developed for therapy because they had un favourable pharmacokinetics or toxicity. The AAC approach could also expand our arsenal against other notorious intracellular pathogens, such as Mycobacterium tuberculosis.
Alternative strategies to tackle the growing problem of antibiotic resistance are also emerging. These include antibiotics that specifically target persistent cells 7 , agents that stimulate the host's antimicrobial defences to augment antibiotic therapy 8, 9 , or harmless 'biocontrol' agents that colonize the host and inhibit pathogen growth 10 . We can hope that such approaches, alongside the AAC strategy presented by Lehar et 
